Company Overview

In March 2018, IQ-AI Ltd acquired Imaging Biometrics, LLC, a Wisconsin USA-based healthcare imaging software company. In addition to providing regulatory consulting services, Imaging Biometrics supplies medical technology solutions and has a strong neuroimaging product portfolio. This is the second acquisition made by IQ-AI in the medical imaging space after acquiring Stone Checker Software Ltd in 2017.

Please find more information on the Imaging Biometrics website and the StoneChecker website

Investor Relations

IQ-AI Directors

Trevor Brown

Trevor Brown is the Chief Executive Director of IQ-AI Ltd. Most recently a director of Feedback plc and MRS plc, Trevor is currently a director of Remote Monitored Systems plc and Braveheart Investment Group plc.


Qu Li has been appointed Non-Executive Director of IQ-AI Ltd. With over 25 years of experience in international mergers, acquisitions and joint ventures, Dr Li has completed turnkey transactions ranging from $5m-$200m and raised more than $300 million over the last 10 years. Dr. Li is the founder and Chairman of China Ventures Ltd, a leading consultancy and venture capital company, specialising in Sino/Western business and offering a wide range of skills associated with international business transactions. Dr. Li relocated to the UK over 20 years ago, where she obtained her Doctorate of Philosophy at Leeds University and then established her business base. She is a qualified engineer and a successful business entrepreneur who has worked on activities related to government, industry and commerce in China, South East Asia, South America, Europe and the US for over 20 years.

Apart from her business commitments, Dr. Li devotes great effort, interest and financial support to the development of young entrepreneurs across the globe. She sits on the advisory board of the Business School of Leeds University and is one of the Leaders in Resident for the post graduates.

Vinod Kaushal

Vinod is a non-executive director on the board of IQ-AI Ltd. Vinod is a well-seasoned healthcare industry executive with nearly 30 years’ experience in predominantly commercial and general management roles. He has worked nationally, regionally and globally for a number of blue chip and SME companies.

Having been part of the team which orchestrated the international launch of Losec®/Prilosec® at Astra to its place as the global No. 1 selling pharmaceutical, Vinod was Head of Global Marketing at Novo Nordisk, Senior Vice President Fresenius Kabi, Vice President of Amersham/GE Health’s Neurology business, Vice President at Royal Numico/Danone and CEO of SPL amongst other pivotal roles.

Since leaving Big Pharma, Vinod has recently been focused on entrepreneurial activities with a number of successful SMEs in the Pharma/Healthcare space. With an impressive deal sheet to his name, Vinod has been involved in various IP and business acquisitions. His career has seen him relate to investors on several global stock exchanges and he is an accomplished external speaker. Vinod holds a BSc (Hons) in Biochemistry from Warwick University and a MBA from Henley Business School.

Company Advisors

  • Peterhouse Corporate Finance Limited
  • New Liverpool House, 15 Eldon Street, London, EC2M 7LD
  • Welbeck Associates, 30 Percy Street, London, W1T 2DB
  • Barclays Bank plc
  • 39 / 41 Broad Street
  • St Helier
  • Jersey
  • JE4 8PU
  • Share Registrars Ltd
  • Correspondence Address: Suite E, First Floor, 9 Lion & Lamb Yard, Farnham, Surrey GU9 7LL

IQ-AI Ltd ordinary shares are traded on the Standard List of the London Stock Exchange. The IQ-AI Ltd ticker code is IQAI
There are no restrictions on the transfer of shares.

Significant Shareholders

As at 1 October 2019, as far as the Directors are aware, the following shareholders
are interested in 3% or more of the issued share capital of the Company.

Total shares in issue: 139,830,982 Ordinary Shares of £0.01 each

News & Announcements Highlights


P. O. Box 264
Forum 4, Grenville Street
St Helier, Jersey, Channel Islands

IQ-AI Ltd is a Jersey Registered Public Company #2044